KYORIN Pharmaceutical Co., Ltd. (TYO:4569)

KYORIN Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	13,668	11,802	15,021	13,886	19,394	26,994
Short-Term Investments	3,287	3,279	1,493	99	-	500
Cash & Short-Term Investments	16,955	15,081	16,514	13,985	19,394	27,494
Cash Growth	2.03%	-8.68%	18.08%	-27.89%	-29.46%	-10.86%
Receivables	40,402	47,298	47,541	47,672	47,250	41,636
Inventory	67,204	67,788	65,730	53,470	48,025	42,217
Other Current Assets	5,532	4,975	6,349	4,183	4,361	5,029
Total Current Assets	130,093	135,142	136,134	119,310	119,030	116,376
Property, Plant & Equipment	30,194	30,506	30,303	28,950	25,834	24,334
Long-Term Investments	24,429	25,720	21,831	23,882	24,469	27,140
Other Intangible Assets	3,891	4,085	4,757	5,088	5,393	3,289
Long-Term Deferred Tax Assets	-	-	591	448	1,316	783
Other Long-Term Assets	2	2	2	1	3	2
Total Assets	188,609	195,455	193,618	177,679	176,045	171,924

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	11,680	14,441	15,517	14,265	13,762	10,896
Accrued Expenses	1,117	2,157	2,226	2,198	2,182	2,295
Short-Term Debt	2,600	2,600	7,400	10,100	10,300	10,300
Current Portion of Long-Term Debt	254	273	200	10,200	-	-
Current Portion of Leases	-	129	135	87	134	147
Current Income Taxes Payable	418	898	3,176	923	2,027	530
Other Current Liabilities	9,038	8,870	6,457	7,718	6,578	8,014
Total Current Liabilities	25,107	29,368	35,111	45,491	34,983	32,182
Long-Term Debt	20,389	20,444	20,235	435	10,636	10,836
Long-Term Leases	-	339	469	124	207	341
Pension & Post-Retirement Benefits	95	95	575	117	3,721	2,885
Long-Term Deferred Tax Liabilities	1,526	1,915	59	185	-	175
Other Long-Term Liabilities	1,188	870	885	545	1,038	998
Total Liabilities	48,305	53,031	57,334	46,897	50,585	47,417

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	700	700	700	700	700	700
Additional Paid-In Capital	4,752	4,752	4,752	4,752	4,752	4,752
Retained Earnings	130,218	131,545	142,789	136,774	134,396	132,710
Treasury Stock	-5,929	-5,929	-17,349	-17,350	-17,666	-17,671
Comprehensive Income & Other	10,563	11,356	5,392	5,906	3,278	4,016
Shareholders' Equity	140,304	142,424	136,284	130,782	125,460	124,507
Total Liabilities & Equity	188,609	195,455	193,618	177,679	176,045	171,924

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	23,243	23,785	28,439	20,946	21,277	21,624
Net Cash (Debt)	-6,288	-8,704	-11,925	-6,961	-1,883	5,870
Net Cash Growth	-	-	-	-	-	-34.50%
Net Cash Per Share	-109.46	-151.51	-207.58	-121.29	-32.86	102.44
Filing Date Shares Outstanding	57.45	57.46	57.46	57.45	57.3	57.3
Total Common Shares Outstanding	57.45	57.46	57.46	57.45	57.3	57.3
Working Capital	104,986	105,774	101,023	73,819	84,047	84,194
Book Value Per Share	2442.35	2478.72	2371.97	2276.50	2189.38	2172.82
Tangible Book Value	136,413	138,339	131,527	125,694	120,067	121,218
Tangible Book Value Per Share	2374.62	2407.63	2289.18	2187.93	2095.27	2115.43

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 4, 2026

Data Sources Report a data error